These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29146210)

  • 1. Novel intracellular transport-refractory mutations in KCNH2 identified in patients with symptomatic long QT syndrome.
    Fukumoto D; Ding WG; Wada Y; Fujii Y; Ichikawa M; Takayama K; Fukuyama M; Kato K; Itoh H; Makiyama T; Omatsu-Kanbe M; Matsuura H; Horie M; Ohno S
    J Cardiol; 2018 Apr; 71(4):401-408. PubMed ID: 29146210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trafficking defect and proteasomal degradation contribute to the phenotype of a novel KCNH2 long QT syndrome mutation.
    Mihic A; Chauhan VS; Gao X; Oudit GY; Tsushima RG
    PLoS One; 2011 Mar; 6(3):e18273. PubMed ID: 21483829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional and clinical characterization of a novel homozygous KCNH2 missense variant in the pore region of Kv11.1 leading to a viable but severe long-QT syndrome.
    Delinière A; Jaupart L; Janin A; Millat G; Boulin T; Andrini O; Chevalier P
    Gene; 2024 Mar; 897():148076. PubMed ID: 38086455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional effects of a missense mutation in HERG associated with type 2 long QT syndrome.
    Amorós I; Jiménez-Jáimez J; Tercedor L; Barana A; Gómez R; de la Fuente MG; Dolz-Gaitón P; Alvarez M; Martínez-Espín E; Lorente JA; Melgares R; Tamargo J; Delpón E; Caballero R
    Heart Rhythm; 2011 Mar; 8(3):463-70. PubMed ID: 21109023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue of protein expression defects may not be enough to abolish the pro-arrhythmic phenotype of long QT type 2 mutations.
    Perry MD; Ng CA; Phan K; David E; Steer K; Hunter MJ; Mann SA; Imtiaz M; Hill AP; Ke Y; Vandenberg JI
    J Physiol; 2016 Jul; 594(14):4031-49. PubMed ID: 26958806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism.
    Anderson CL; Delisle BP; Anson BD; Kilby JA; Will ML; Tester DJ; Gong Q; Zhou Z; Ackerman MJ; January CT
    Circulation; 2006 Jan; 113(3):365-73. PubMed ID: 16432067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trafficking-deficient long QT syndrome mutation KCNQ1-T587M confers severe clinical phenotype by impairment of KCNH2 membrane localization: evidence for clinically significant IKr-IKs alpha-subunit interaction.
    Biliczki P; Girmatsion Z; Brandes RP; Harenkamp S; Pitard B; Charpentier F; Hébert TE; Hohnloser SH; Baró I; Nattel S; Ehrlich JR
    Heart Rhythm; 2009 Dec; 6(12):1792-801. PubMed ID: 19959132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of loss of Kv11.1 K+ current in mutant T421M-Kv11.1-expressing rat ventricular myocytes: interaction of trafficking and gating.
    Balijepalli SY; Lim E; Concannon SP; Chew CL; Holzem KE; Tester DJ; Ackerman MJ; Delisle BP; Balijepalli RC; January CT
    Circulation; 2012 Dec; 126(24):2809-18. PubMed ID: 23136156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overlapping LQT1 and LQT2 phenotype in a patient with long QT syndrome associated with loss-of-function variations in KCNQ1 and KCNH2.
    Cordeiro JM; Perez GJ; Schmitt N; Pfeiffer R; Nesterenko VV; Burashnikov E; Veltmann C; Borggrefe M; Wolpert C; Schimpf R; Antzelevitch C
    Can J Physiol Pharmacol; 2010 Dec; 88(12):1181-90. PubMed ID: 21164565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel mutation in the Per-Arnt-Sim domain of KCNH2 causes a malignant form of long-QT syndrome.
    Rossenbacker T; Mubagwa K; Jongbloed RJ; Vereecke J; Devriendt K; Gewillig M; Carmeliet E; Collen D; Heidbüchel H; Carmeliet P
    Circulation; 2005 Mar; 111(8):961-8. PubMed ID: 15699249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Invalidation of Putative Sudden Infant Death Syndrome-Associated Variants in the
    Smith JL; Tester DJ; Hall AR; Burgess DE; Hsu CC; Elayi SC; Anderson CL; January CT; Luo JZ; Hartzel DN; Mirshahi UL; Murray MF; Mirshahi T; Ackerman MJ; Delisle BP
    Circ Arrhythm Electrophysiol; 2018 May; 11(5):e005859. PubMed ID: 29752375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tbx20 controls the expression of the KCNH2 gene and of hERG channels.
    Caballero R; Utrilla RG; Amorós I; Matamoros M; Pérez-Hernández M; Tinaquero D; Alfayate S; Nieto-Marín P; Guerrero-Serna G; Liu QH; Ramos-Mondragón R; Ponce-Balbuena D; Herron T; Campbell KF; Filgueiras-Rama D; Peinado R; López-Sendón JL; Jalife J; Delpón E; Tamargo J
    Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E416-E425. PubMed ID: 28049825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum.
    Smith JL; Reloj AR; Nataraj PS; Bartos DC; Schroder EA; Moss AJ; Ohno S; Horie M; Anderson CL; January CT; Delisle BP
    Am J Physiol Cell Physiol; 2013 Nov; 305(9):C919-30. PubMed ID: 23864605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenergic regulation of the rapid component of delayed rectifier K+ current: implications for arrhythmogenesis in LQT2 patients.
    Zankov DP; Yoshida H; Tsuji K; Toyoda F; Ding WG; Matsuura H; Horie M
    Heart Rhythm; 2009 Jul; 6(7):1038-46. PubMed ID: 19419905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long QT Syndrome Type 2: Emerging Strategies for Correcting Class 2
    Ono M; Burgess DE; Schroder EA; Elayi CS; Anderson CL; January CT; Sun B; Immadisetty K; Kekenes-Huskey PM; Delisle BP
    Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32759882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CAV3 in long-QT syndrome: clinical and functional assessment of a caveolin-3/Kv11.1 double heterozygote versus caveolin-3 single heterozygote.
    Hedley PL; Kanters JK; Dembic M; Jespersen T; Skibsbye L; Aidt FH; Eschen O; Graff C; Behr ER; Schlamowitz S; Corfield V; McKenna WJ; Christiansen M
    Circ Cardiovasc Genet; 2013 Oct; 6(5):452-61. PubMed ID: 24021552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined gating and trafficking defect in Kv11.1 manifests as a malignant long QT syndrome phenotype in a large Danish p.F29L founder family.
    Kanters JK; Skibsbye L; Hedley PL; Dembic M; Liang B; Hagen CM; Eschen O; Grunnet M; Christiansen M; Jespersen T
    Scand J Clin Lab Invest; 2015; 75(8):699-709. PubMed ID: 26403377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes.
    O'Hare BJ; John Kim CS; Hamrick SK; Ye D; Tester DJ; Ackerman MJ
    Circ Genom Precis Med; 2020 Oct; 13(5):466-475. PubMed ID: 32940533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic basis for type 2 long QT syndrome caused by KCNH2 mutations that disrupt conserved arginine residues in the voltage sensor.
    McBride CM; Smith AM; Smith JL; Reloj AR; Velasco EJ; Powell J; Elayi CS; Bartos DC; Burgess DE; Delisle BP
    J Membr Biol; 2013 May; 246(5):355-64. PubMed ID: 23546015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The mechanistic rote of KCNH2 gene L413P and L559H mutations in long QT syndrome].
    Li CL; Hu DY; Liu WL; Qi SY; Wang HT; Li L; Gong QM; Zhou ZF
    Zhonghua Nei Ke Za Zhi; 2007 Oct; 46(10):838-41. PubMed ID: 18218237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.